Search Results - "de LLano, Maria Paz Queipo"

Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial by Ribera, Josep-Maria, Morgades, Mireia, Garcia-Calduch, Olga, Sirvent, Maialen, Buendia, Buenaventura, Cervera, Marta, Luzardo, Hugo, Hernandez-Rivas, Jesus-Maria, Sitges, Marta, Garcia-Cadenas, Irene, Abrisqueta, Pau, Montesinos, Pau, Bastos-Oreiro, Mariana, De Llano, Maria-Paz Queipo, Bravo, Pilar, Torrent, Anna, Herrera, Pilar, Garcia-Guinon, Antoni, Vall-Llovera, Ferran, Serrano, Josefina, Terol, Maria-Jose, Bergua, Juan-Miguel, Garcia-Noblejas, Ana, Barrenetxea, Cristina, Llorente, Laura, Garcia-Belmonte, Daniel, Gimeno, Eva, Cladera, Antonia, Mercadal, Santiago, Sancho, Juan-Manuel

“…High dose-intensive or infusional intermediate-dose immunochemotherapy is highly effective treatment for Burkitt lymphoma irrespective of human…”
Get full text

Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease by Hoyos, Montserrat, Nomdedeu, Josep F., Esteve, Jordi, Duarte, Rafael, Ribera, Josep M., Llorente, Andreu, Escoda, Lourdes, Bueno, Javier, Tormo, Mar, Gallardo, David, de Llano, Maria Paz Queipo, Martí, Josep M., Aventín, Anna, Mangues, Ramón, Brunet, Salut, Sierra, Jorge

“…Purpose Most patients with acute myeloid leukemia (AML) and genetic rearrangements involving the core binding factor (CBF) have favorable prognosis. In…”
Get full text

Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain by Ribera, Josep-Maria, García, Olga, Buendía-Ureña, Buenaventura, Terol, Maria-José, Vicent, Ana, Vall-Llovera, Ferran, Bergua, Juan, García-Cadenas, Irene, Esteve, Jordi, Ribera, Jordi, Acuña-Cruz, Evelyn, Herrera, Pilar, Hernández-Rivas, Jesus-Maria, Abrisqueta, Pau, González-Campos, José, Rodríguez, Carlos, Bastos-Oreiro, Mariana, Genescà, Eulàlia, Caminos, Nerea, Queipo de Llano, Maria-Paz, Cladera, Antònia, Sancho, Juan-Manuel

Get full text

The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature by Díaz-Beyá, Marina, Brunet, Salut, Nomdedéu, Josep, Pratcorona, Marta, Cordeiro, Anna, Gallardo, David, Escoda, Lourdes, Tormo, Mar, Heras, Inmaculada, Ribera, Josep Maria, Duarte, Rafael, de Llano, María Paz Queipo, Bargay, Joan, Sampol, Antonia, Nomdedeu, Meritxell, Risueño, Ruth M, Hoyos, Montserrat, Sierra, Jorge, Monzo, Mariano, Navarro, Alfons, Esteve, Jordi

“…Long non-coding RNAs (lncRNAs) are deregulated in several tumors, although their role in acute myeloid leukemia (AML) is mostly unknown.We have examined the…”
Get full text

Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain by Torrent, Anna, Morgades, Mireia, García‐Calduch, Olga, Llano, María Paz Queipo, Montesinos, Pau, Navarro, Irene, Hernández‐Rivas, Jesús María, Bárez‐García, Abelardo, González‐Campos, José, Oiartzabal, Itziar, Valero, Marta, Cervera, Marta, Zudaire, Teresa, Albors‐Ferreiro, Manuel, López‐Godino, Oriana, Gil‐Cortés, Cristina, Villalón, Lucía, Saldaña, Raquel, Ribera, Josep‐María

“…Introduction The prognosis of relapsed B cell precursor acute lymphoblastic leukemia (B‐ALL) is poor and few patients can be successfully rescued with…”
Get full text

Complex Measurements May Be Required to Establish the Prognostic Impact of Immunophenotypic Markers in AML by García-Dabrio, Maria Concepcion, Hoyos, Montserrat, Brunet, Salut, Tormo, Mar, Ribera, Josep-Maria, Esteve, Jordi, Gallardo, David, Duarte, Rafael F., de Llano, Maria Paz Queipo, Bargay, Joan, Martí-Tutusaus, Josep M., Heras, Inmaculada, Garcia, Antoni, Salamero, Olga, Aventin, Anna, Lecrevisse, Quentin, Orfao, Alberto, Sierra, Jorge, Nomdedéu, Josep F.

“…Objectives The prognostic impact of immunophenotypic markers in acute myeloid leukemia (AML) is controversial. Methods We retrospectively analyzed the value of…”
Get full text

Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival by Guillem, Vicent, Calabuig, Marisa, Brunet, Salut, Esteve, Jordi, Escoda, Lourdes, Gallardo, David, Ribera, Josep-Maria, Queipo de Llano, María Paz, Arnan, Montserrat, Pedro, Carme, Amigo, María Luz, Martí-Tutusaus, Josep M., García-Guiñón, Antoni, Bargay, Joan, Sampol, Antonia, Salamero, Olga, Font, Llorenç, Talarn, Carme, Hoyos, Montserrat, Díaz-Beyá, Marina, Garrido, Ana, Navarro, Blanca, Nomdédeu, Josep, Sierra, Jordi, Tormo, Mar

“…Vascular endothelial growth factor C (VEGFC) stimulates leukemia cell proliferation and survival, and promotes angiogenesis. We studied VEGFC expression in…”
Get full text

Outcomes and prognostic factors of adults with refractory or relapsed T‐cell acute lymphoblastic leukemia included in measurable residual disease‐oriented trials by Ribera, Josep‐Maria, Morgades, Mireia, Genescà, Eulàlia, Chapchap, Eduardo‐Cerello, Montesinos, Pau, Acuña‐Cruz, Evelyn, Gil, Cristina, García‐Cadenas, Irene, Barba, Pere, González‐Campos, José, Queipo de Llano, María‐Paz, Torrent, Anna, Ribera, Jordi, Granada, Isabel, Bernal, Teresa, Díaz‐Beyá, Marina, Amigo, María‐Luz, Coll, Rosa, Tormo, Mar, Vall‐llovera, Ferran, Gómez‐Centurión, Ignacio, Sánchez‐Sánchez, María‐José, Soria, Beatriz, Cladera, Antonia, Artola, María‐Teresa, Garcia‐Guiñon, Antoni, Giménez‐Conca, Alberto, Amador, María‐Lourdes, Martínez‐Sánchez, Pilar, Algarra, Jesús‐Lorenzo, Vidal, María‐Jesús, Alonso, Natalia, Maluquer, Clara, Llorente, Laura, García‐Boyero, Raimundo, Ciudad, Juana, Feliu, Evarist, Orfao, Alberto

“…Despite high complete remission (CR) rates with frontline therapy, relapses are frequent in adults with T‐cell acute lymphoblastic leukemia (T‐ALL) with…”
Get full text

Clinical experience using intrathecal liposomal cytarabine to manage neoplastic meningitis in three patients with acute promyelocytic leukemia by Duarte, Rafael F, Arnan, Monserrat, Sánchez-Ortega, Isabel, de Llano, Maria Paz Queipo, Abellán, Pascual Fernández

Get full text

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol by Bataller, Alex, Garrido, Ana, Guijarro, Francesca, Oñate, Guadalupe, Diaz-Beyá, Marina, Arnan, Montserrat, Tormo, Mar, Vives, Susana, de Llano, María Paz Queipo, Coll, Rosa, Gallardo, David, Vall-Llovera, Ferran, Escoda, Lourdes, Garcia-Guiñon, Antonio, Salamero, Olga, Sampol, Antònia, Merchan, Brayan M., Bargay, Joan, Castaño-Díez, Sandra, Esteban, Daniel, Oliver-Caldés, Aina, Rivero, Andrea, Mozas, Pablo, López-Guerra, Mònica, Pratcorona, Marta, Zamora, Lurdes, Costa, Dolors, Rozman, Maria, Nomdedéu, Josep F., Colomer, Dolors, Brunet, Salut, Sierra, Jorge, Esteve, Jordi

“…The 2017 European LeukemiaNet (ELN 2017) guidelines for the diagnosis and management of acute myeloid leukemia (AML) have become fundamental guidelines to…”
Get full text

P1147: FEASIBILITY AND OUTCOME AFTER DOSE REDUCTION OF IMMUNOCHEMOTHERAPY IN YOUNG ADULTS WITH BURKITT LYMPHOMA AND LEUKEMIA. RESULTS OF THE BURKIMAB14 TRIAL by Maria Ribera, Josep, Morgades, Mireia, García‐Calduch, Olga, Sirvent, Maialen, Buendía Ureña, Buenaventura, Cervera, Marta, Luzardo, Hugo, Hernández Rivas, Jesus, Sitges Arriaga, Marta, Garcia Cadenas, Irene, Abrisquet Acosta, Pablo, Montesinos, Pau, Bastos Oreiro, Mariana, Queipo de Llano, María‐Paz, Bravo, Pilar, Torrent, Anna, Puente, Maria Pilar Herrera, Garcia‐Guiñon, Antonio, Vall‐Llovera Calmet, Ferran, Serrano, Josefina, Terol, Maria J, Burgues, Juan Miguel Bergua, García‐Noblejas, Ana, Barrenetxea, Cristina, Llorente, Laura, García‐Belmonte, Daniel, Gimeno, Eva, Cladera, Antonia, Mercadal Vilchez, Santiago, Manuel Sancho, Juan

Get full text

Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012) by Bataller, Alex, Garrido, Ana, Guijarro, Francesca, Diaz-Beyá, Marina, Oñate, Guadalupe, Hoyos, Montserrat, Arnan, Montserrat, Tormo, Mar, Vives, Susana, Queipo De Llano, Maria Paz, Salamero, Olga, Coll, Rosa, Gallardo, David, Vall-Llovera, Ferran, Escoda, Lourdes, Sampol, Antonia, Garcia-Guiñon, Antonio, Merchan, Brayan, Bargay, Joan, Lopez-Guerra, Monica, Pratcorona, Marta, Zamora, Lurdes, Brunet, Salut, Nomdedeu, Josep F, Sierra, Jorge, Esteve, Jordi

“…Introduction The European LeukemiaNet (ELN) 2017 classification for acute myeloid leukemia (AML) stratifies patients in 3 risk categories, according to genetic…”
Get full text

Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials by Ribera, Josep-Maria, Chapchap, Eduardo Cerello, Morgades, Mireia, Genescà, Eulàlia, Gil, Cristina, García-Cadenas, Irene, Barba, Pere, González-Campos, José, Torrent, Anna, Bernal del Castillo, Teresa, Queipo De Llano, Maria Paz, Amigo, María-Luz, Tormo, Mar, Coll, Rosa, Vall-Llovera, Ferran, Ribera, Jordi, Sanchez, Maria Jose, Soria, Beatriz, Cladera, Antonia, Artola, María Teresa, Garcia-Guiñon, Antoni, Giménez Conca, Alberto, Barciela, Lourdes Amador, Ciudad, Juana, Orfao, Alberto

“…Introduction and objective. Despite a high complete remission (CR) rate obtained with frontline therapy most adults with T-ALL eventually relapse. Although…”
Get full text

Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival by Garrido, Ana, Hoyos, Montserrat, Diaz-Beyá, Marina, Arnan, Montserrat, Vives, Susana, Calabuig, Marisa, Salamero, Olga, Gallardo, David, Queipo De Llano, Maria Paz, Escoda, Lourdes, Sampol, Antonia, Vall-Llovera, Ferran, Garcia-Guiñon, Antonio, Brayan, Merchan, Bargay, Joan, Torres, J Pio, Ortin, Xavier, Amigo, M Luz, Moraleda, Jose Maria, Falantes, José F., Valcarcel, David, Tormo, Mar, Ribera, Josep-Maria, Brunet, Salut, Sureda Balari, Anna, Esteve, Jordi, Sierra, Jorge

“…The progress in the understanding of pathophysiology of AML has allowed the identification of genetic and immune abnormalities with prognostic impact on…”
Get full text

Prognostic Impact of the Interaction between DNMT3A mutation and Internal Tandem Duplication of the FLT3 Gene (FLT3-ITD) in Patients with De Novo Mutated NPM1 (NPM1mut) acute Myeloid Leukemia by Oñate, Guadalupe, Garrido, Ana, Esteve, Jordi, Coll, Rosa, Arnan Sangerman, Montserrat, Vives, Susana, Sampol, Antonia, Tormo, Mar, Escoda, Lourdes, Queipo De Llano, Maria Paz, Garcia-Guiñon, Antoni, Bargay, Joan, Salamero, Olga, Aljarilla, Alba, Brunet, Salut, Sierra, Jorge, Nomdedeu, Josep, Pratcorona, Marta

“…Introduction The association of NPM1mut and FLT3-ITD in de novo acute myeloid leukemia (AML) with intermediate-risk cytogenetics has different prognostic…”
Get full text

Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease by Sierra, Jorge, Garrido, Ana, Diaz Beya, Marina, Hoyos, Montserrat, Calabuig, Marisa, Vives, Susana, Arnan Sangerman, Montserrat, Queipo De Llano, Maria Paz, Salamero, Olga, Vall-Llovera, Ferran, Bataller, Alex, Guijarro, Francisca, Escoda, Lourdes, Garcia-Guiñon, Antonio, Merchan, Brayan, Ortin, Xavier, Sanchez Ortega, Isabel, Pratcorona, Marta, Bargay, Joan, Sampol, Antonia, Nomdedeu, Josep, Gallardo, David, Ribera, Josep-Maria, Tormo, Mar, Esteve, Jordi, Brunet, Salut

“…BACKGROUND: AML risk classification is based on genetics (cytogenetics and molecular features) and more recently also on minimal residual disease (MRD) after…”
Get full text

Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults up to the Age of 70 Years by Sierra, Jorge, Garrido, Ana, Vives, Susana, Queipo De Llano, Maria Paz, Guàrdia, Ramon, Diaz-Beyá, Marina, Calabuig, Marisa, Pratcorona, Marta, Arnan Sangerman, Montserrat, Salamero, Olga, Cervera, Marta, Sampol, Antonia, Garcia-Guiñon, Antoni, Pedro, Carme, Marti, Josep M, Bargay, Joan, Font, Llorenç, Nomdedeu, Josep F, Hoyos, Montserrat, Escoda, Lourdes, Batlle, Montserrat, Merchan, Bryan, Sanchez-Ortega, Isabel, Tormo, Mar, Gallardo, David, Ribera, Josep-Maria, Esteve, Jordi, Brunet, Salut

“…BACKGROUND: Current AML risk stratification relies on genetic data (cytogenetics and molecular characteristics) and minimal residual disease (MRD) assessment…”
Get full text

Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach by Nomdedéu, Josep F., Puigdecanet, Eulalia, Bussaglia, Elena, Hernández, Juan José, Carricondo, Maite, Estivill, Camino, Martí‐Tutusaus, Josep Maria, Tormo, Mar, Zamora, Lurdes, Serrano, Elena, Perea, Granada, Llano, Maria Paz Queipo, García, Antoni, Sánchez‐Ortega, Isabel, Ribera, Josep Maria, Nonell, Lara, Aventin, Anna, Solé, Francesc, Brunet, Maria Salut, Sierra, Jorge

“…Deoxyribonucleic acid microarrays allow researchers to measure mRNA levels of thousands of genes in a single experiment and could be useful for diagnostic…”
Get full text

Use of Granulocyte Colony-Stimulating Factor (G-CSF) Together with Induction and Intensification Chemotherapy (CT) in Adults with Primary Acute Myeloid Leukemia (AML) by Brunet, Salut, Perea, Granada, Ribera, Josep M., Esteve, Jordi, Tormo, Mar, Berlanga, Juan, Bueno, Javier, Llorente, Andreu, Moraleda, Jose M., Guardia, Ramon, Besalduch, Joan, Torres, Pio, de Llano, Maria Paz Queipo, Marti, Josep M., Pedro, Carmen, Bargay, Joan, Sanchez, Josep M., Vivancos, Pilar, Feliu, Evaristo, Montserrat, Emili, Sierra, Jorge

“…We analyzed the complete remission (CR) rate and toxicity in patients (pts) with “de novo” AML enrolled in an intensive CT protocol including induction and…”
Get full text

Germline Polymorphisms Provide Strong Prognostic Information in Intermediate Risk Acute Myeloblastic Leukemia (AML) by Urbano-Ispizua, Alvaro, Brunet, Salut, Monzo, Mariano, Perea, Granada, Navarro, Alfons, Esteve, Jordi, Berlanga, Juan, Ribera, Josep-Maria, Bueno, Javier, Llorente, Andreu, Besalduch, Juan, Guardia, Ramon, Tormo, Mar, Pedro, Carmen, Sanchez, Juan-Maria, Torres, Pio, de Llano, Maria-Paz Queipo, Font, Llorens, Moraleda, Jose-Maria, Marti, Josep-Maria, Vivancos, Pilar, Peñarubia, Maria-Jesus, Nomdedeu, Josep, Montserrat, Emili, Sierra, Jorge

“…In this study we tested whether distinct patterns of functional genomic polymorphisms in genes involved in drug metabolic pathways (GSTT1, SULT1C2, CD-EX,…”
Get full text